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Abstract 
 
 
Background: Febrile neutropenia (FN) occurs following myelosuppressive 
chemotherapy and is associated with morbidity, mortality, costs, and chemotherapy 
reductions and delays. Granulocyte colony-stimulating factors (G-CSFs) stimulate 
neutrophil production and may reduce FN incidence when given prophylactically 
following chemotherapy. 
 
Methods: A systematic review and meta-analysis assessed the effectiveness of G-CSFs 
(pegfilgrastim, filgrastim or lenograstim) in preventing FN in adults undergoing 
chemotherapy for solid tumours or lymphoma. G-CSFs were compared with no 
primary G-CSF prophylaxis and with one another. Nine databases were searched in 
December 2009. Meta-analysis used a random effects model due to heterogeneity. 
 
Results: Twenty studies compared primary G-CSF prophylaxis with no primary G-CSF 
prophylaxis: five studies of pegfilgrastim; ten of filgrastim; and five of lenograstim. All 
three G-CSFs significantly reduced FN incidence, with relative risks of 0.30 (95% CI: 
0.14 – 0.65) for pegfilgrastim, 0.57 (95% CI: 0.48 – 0.69) for filgrastim, and 0.62 (95% 
CI: 0.44 – 0.88) for lenograstim. Five studies compared pegfilgrastim with filgrastim; FN 
incidence was significantly lower for pegfilgrastim than filgrastim, with relative risk 
0.66 (95% CI: 0.44 – 0.98). 
 
Conclusions: Primary prophylaxis with G-CSFs significantly reduces FN incidence in 
adults undergoing chemotherapy for solid tumours or lymphoma. Pegfilgrastim 
reduces FN incidence to a significantly greater extent than filgrastim. 
 
 
 
Keywords: febrile neutropenia, G-CSFs, granulocyte colony-stimulating factors, meta- 
analysis, prophylaxis, systematic review 
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Introduction 
 
Neutropenia is the major dose-limiting toxicity of many chemotherapy regimens. 
Grade 3 and grade 4 neutropenia are defined as a neutrophil count <1.0 x 109/L and 
<0.5 x 109/L respectively. Febrile neutropenia (FN) is defined as neutropenia with 
fever, usually indicating infection, and is associated with substantial morbidity, 
mortality, and costs [1]. The direct risk of mortality associated with FN has been 
estimated as 9.5% (95% confidence interval [CI]: 9.2%, 9.8%) in a study of 41,779 
cancer patients hospitalised with FN.[1] Management of FN often requires lengthy 
hospitalisation [1], with associated costs and detrimental effects on quality of life [2;3]. 
In addition, an FN episode has been shown to increase the risk of chemotherapy dose 
reductions and delays [4]. Unplanned reductions in chemotherapy dose may cause 
further deaths from cancer in the long-term; in a retrospective analysis of breast 
cancer patients with a 30-year follow-up, the survival rate was 40% (95% CI: 26%, 
55%) among patients receiving at least 85% of their planned dose, but only 21% (95% 
CI: 14%, 26%) among patients who received less than 85% [5]. 
 
Recombinant human granulocyte colony-stimulating factors (G-CSFs) stimulate 
production of mature, functional neutrophils [6]. G-CSFs have been shown to reduce 
the incidence of FN when used as prophylaxis following chemotherapy. Three G-CSFs 
are currently in common usage: filgrastim, pegfilgrastim, and lenograstim. Filgrastim 
and lenograstim are administered as a series of daily injections; clinical studies suggest 
an average of 11 injections per chemotherapy cycle are required to achieve recovery of 
the absolute neutrophil count (ANC) to within the normal range [7-10]. Pegfilgrastim is 
administered as a single injection per chemotherapy cycle [11;12]. G- CSFs may be 
administered as primary prophylaxis (in every chemotherapy cycle from cycle 1) or as 
secondary prophylaxis (in all remaining cycles following a neutropenic event such as 
FN or prolonged severe neutropenia). The overall FN risk is dependent on 
chemotherapy regimen as well as individual patient risk factors such as age, 
performance status and disease stage [13]. Guidelines from the European 
Organisation for Research and Treatment of Cancer (EORTC) [13], the American 
Society of Clinical Oncology (ASCO) [14] and the National Comprehensive Cancer 
Network (NCCN) [15] recommend that prophylactic G-CSFs should be used where 
the risk of FN associated with the chemotherapy regimen is greater than or equal to 
20%, and may be considered where the risk is 10-20%, particularly where additional 
patient risk factors are present. 
 
This paper reports a systematic review and meta-analysis of the effect of primary G- 
CSF prophylaxis (with pegfilgrastim, filgrastim or lenograstim) on incidence of FN. 
The effect of each G-CSF is assessed in comparison with no primary G-CSF 
prophylaxis and in comparison with other G-CSFs. 
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Methods 
 
Search strategy 
A systematic search was undertaken to identify RCTs of pegfilgrastim, filgrastim or 
lenograstim, compared with no primary G-CSF or with one another, for the 
prevention of FN following chemotherapy. A previous systematic review by Kuderer et 
al. [16] presented a meta-analysis of FN incidence within RCTs of primary G-CSF 
prophylaxis versus no primary G-CSF prophylaxis, while a systematic review by Pinto 
et al. [17] meta-analysed RCTs of primary prophylaxis using pegfilgrastim versus 
filgrastim. The literature searches within these previous reviews were conducted 
during 2006. Therefore, databases were searched from 2006 onwards, whereas 
studies published prior to 2006 were identified from the two existing reviews. 
Searches were undertaken in December 2009. The following databases were 
searched: Medline, Medline in Process, EMBASE, Science Citation Index, Cochrane 
Database of Systematic Reviews, Cochrane CENTRAL Register of Controlled Trials, 
Database of Abstracts of Reviews of Effects (DARE), Health Technology Assessment 
Database and NHS Economic Evaluation Database (NHS-EED). The Medline search 
strategy was designed with reference to the previous two reviews, and comprised 
subject headings and text words for G-CSFs combined with a search filter to identify 
RCTs (Appendix 1). Searches were not restricted by language. Bibliographies of 
retrieved papers were searched for any additional relevant studies. 
 
Inclusion and exclusion criteria 
Studies were considered suitable for inclusion if they assessed primary G-CSF 
prophylaxis (pegfilgrastim, filgrastim or lenograstim) administered 1-3 days after the 
completion of chemotherapy, versus a different G-CSF or versus no primary G-CSF 
prophylaxis. Studies were only included if they reported incidence of FN. For 
consistency with the two existing systematic reviews [16;17], only studies of adult 
cancer patients with solid tumours or lymphoma were included. Studies allowing 
concomitant antibiotic prophylaxis were included if identical prophylaxis was 
administered in both study arms. The following study types were excluded: studies of 
G-CSFs for treatment of FN; studies in children; studies in patients with leukaemia, 
myeloid malignancies or myelodysplastic syndromes; studies of G-CSFs for stem cell 
mobilisation in bone marrow or peripheral blood stem cell transplantation; economic 
analyses; studies with differing drugs, doses or schedules of chemotherapy in each 
arm; studies with differing doses of the same G-CSF in each arm; and studies not 
published in English. 
 
Outcome measures 
The outcome measure assessed in this review was the incidence of FN over all cycles 
of chemotherapy within each study. FN was chosen as a key clinical outcome due to 
its direct bearing on morbidity, mortality and hospitalisation rates, and also because 
this review was undertaken alongside the development of an economic model which 
utilised FN rate as a key parameter. 
 
Data extraction 
Data was extracted by two reviewers using a form developed for this review and any 
discrepancies were resolved through discussion. 
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Data synthesis 
Meta-analyses were undertaken to compare the effectiveness of G-CSFs versus no 
prophylaxis and versus each other for the prevention of FN. Analyses were 
undertaken using RevMan software (version 5, Cochrane Collaboration). Results for 
each comparison were presented as a pooled relative risk and 95% CIs. Although 
clinical and statistical heterogeneity existed between studies, there was insufficient 
data on individual populations to facilitate separate analyses. Therefore, for 
consistency with existing reviews, all studies were included in the analysis, and a 
random effects model was used. Heterogeneity was presented using the I2 statistic, 
which describes the percentage of the variability in effect estimates that is due to 
heterogeneity rather than sampling error (chance) [18]. 
 
 
 
 
Results 
 
Number and characteristics of included studies 
The flow chart for study inclusion is shown in Figure 1 and the included studies are 
described in Table 1. Studies published from 2006 onwards were identified from the 
literature search, and studies published prior to 2006 were identified from two 
previous reviews [16;17]. In total, 23 citations relating to 25 studies satisfied the 
inclusion criteria: 5 studies of pegfilgrastim vs. no primary G-CSF (within 4 citations) 
[19-22]; 10 studies of filgrastim vs. no primary G-CSF (within 9 citations) [23-31]; 5 
studies of primary lenograstim vs. no primary G-CSF [9;10;32-34]; and 5 studies of 
primary pegfilgrastim vs. primary filgrastim [7;8;35-37.] No studies were identified 
comparing lenograstim with either pegfilgrastim alone or filgrastim alone. 
 
A previous systematic review of prophylactic G-CSF use [16] included only a single 
study of pegfilgrastim versus no primary G-CSF [19]. Our literature search identified 4 
additional RCTs of pegfilgrastim vs. no primary G-CSF, which were conducted in 
populations with colorectal cancer [22], breast cancer (elderly patients) [21], non- 
Hodgkin’s lymphoma [20], and various solid tumours [20]. Our review also identified 
an additional large RCT of filgrastim vs. no primary G-CSF in breast cancer [31]. 
 
There was heterogeneity among trials of all three G-CSFs in terms of cancer type, 
patient age, chemotherapy regimen, number of chemotherapy cycles and cycle length 
(Table 1). Filgrastim and lenograstim were generally given for 10-14 days where the 
chemotherapy cycle length was 3 weeks (and for fewer days in a small number of 
trials with shorter cycle lengths). The comparator arm in some of the studies 
included secondary G-CSFs for those patients having an FN event, and some trials 
allowed prophylactic antibiotics in both arms. Some studies were open-label rather 
than double-blind. 
 
Effectiveness of G-CSFs in preventing febrile neutropenia 
The relative risks of FN incidence are shown in Figure 2 for trials of G-CSF versus no 
primary G-CSF, and in Figure 3 for trials of pegfilgrastim versus filgrastim. The pooled 
relative risks for each G-CSF comparison are summarised in Table 2. Primary 
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prophylaxis with each of the G-CSFs significantly decreased the risk of FN compared 
with no primary G-CSF, with relative risks of 0.30 (95% CI: 0.14 to 0.65) for 
pegfilgrastim, 0.57 (95% CI: 0.48 to 0.69) for filgrastim, and 0.62 (95% CI: 0.44 to 
0.88) for lenograstim. Overall, the relative risk of FN when using any primary G-CSF 
prophylaxis versus no primary G-CSF prophylaxis was 0.51 (95% CI: 0.41 to 0.62). 
There was a relatively high level of statistical heterogeneity in the analyses as shown 
by the I2 statistic, which ranged from 50-76%; this is likely to reflect the variations in 
patient population and chemotherapy regimen described above. 
 
In terms of comparisons between different G-CSFs, the relative risk of FN for 
pegfilgrastim versus filgrastim was 0.66 (95% CI: 0.44 to 0.98). There were no head- 
to-head trials comparing lenograstim to either of the other two G-CSFs. 
 
 
 
 
Discussion 
 
Our systematic review and meta-analyses confirm and strengthen previous evidence 
that primary prophylaxis with each of the three G-CSFs is effective in reducing the 
risk of FN following chemotherapy. In particular, our systematic review identified 4 
further RCTs of pegfilgrastim vs. no primary G-CSF [20-22], whereas at the time of a 
previous systematic review [16] only a single RCT [19] making this comparison was 
available. Although these 5 RCTs comparing pegfilgrastim with no primary G-CSF 
were heterogeneous in terms of clinical population and chemotherapy regimen, the 
pooled relative risk indicated a significant effect of pegfilgrastim in preventing FN. 
Further analyses demonstrated that both filgrastim and lenograstim also significantly 
reduced FN incidence. 
 
This review also strengthens the evidence base regarding the comparative 
effectiveness of the three G-CSFs; in particular, comparison of the “once-per-cycle” 
G-CSF pegfilgrastim versus the “once-daily” G-CSF filgrastim. Meta-analysis of five 
RCTs indicated that FN incidence was significantly lower following primary 
prophylaxis with pegfilgrastim than with filgrastim. This is consistent with the fact 
that the reduction in FN risk for pegfilgrastim versus no primary G-CSF was greater 
than the reduction observed for filgrastim versus no primary G-CSF. 
 
As discussed in previous reviews [16;17], there was heterogeneity among the studies in 
terms of the clinical population (age, cancer type), chemotherapy regimen, and cycle 
length and number. Correspondingly, heterogeneity was observed among the study 
results. Since there was insufficient data to analyse the various populations 
separately, all studies were included in the analysis. The included studies covered a 
range of populations and treatment regimens, as would be observed in clinical 
practice. This variation in clinical population, and the corresponding high levels of 
heterogeneity, indicate that caution should be used when applying the results to 
individual clinical settings. 
 
It may also be relevant to note that the majority of the studies with a 3-week 
chemotherapy cycle length administered filgrastim and lenograstim until ANC 
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recovery as recommended in the product labels (generally for 10-11 days per cycle), 
while in clinical practice these G-CSFs may sometimes be given for a shorter number 
of days, which may impact on effectiveness [38;39]. 
 
 
 
 
Conclusions 
 
This systematic review and meta-analysis demonstrate that primary G-CSF 
prophylaxis is effective in reducing the risk of FN in adults undergoing chemotherapy 
for solid tumours or lymphoma. Additionally, direct and indirect evidence suggests 
that pegfilgrastim reduces the risk of FN to a greater extent than filgrastim. 
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Figure 1: Flow chart for identification of relevant studies 
 
 
 
Potentially relevant citations 
identified and screened for retrieval: 
N = 4197 citations 
 
 
Citations rejected at title 
or abstract stage: 
N = 4177 citations 
 
 
Full texts reviewed: 
N = 20 citations 
 
 
 
Citations rejected at full 
text stage: 
N = 16 citations 
 
 
 
Additional studies identified since previous reviews: 
N = 4 citations relating to 5 studies: 
•  Pegfilgrastim vs no primary G-CSF: 4 additional RCTs (within 
3 citations) 
•  Filgrastim vs no primary G-CSF: 1 additional RCT (1 citation) 
 
 
 
 
 
Studies included from previous reviews: 
N = 19 citations relating to 20 studies 
 
 
 
 
 
 
Total full papers included, from updated search and previous reviews: 
N = 23 citations relating to 25 studies: 
•  Pegfilgrastim vs no primary G-CSF: 5 RCTs (within 4 citations) 
•  Filgrastim vs no primary G-CSF: 10 RCTs (within 9 citations) 
•  Lenograstim vs no primary G-CSF: 5 RCTs 
•  Pegfilgrastim vs filgrastim: 5 RCTs 
•  Pegfilgrastim vs lenograstim: 0 RCTs 
•  Lenograstim vs filgrastim: 0 RCTs 
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Trial Study 
design 
Cancer type Cancer stage Patient age Chemotherapy 
regimen 
N cycles 
(max) 
Cycle 
length 
Arm 1 G-CSF 
strategy b 
Arm 1: N 
analysed 
Arm 1: days 
primary G- 
CSF 
Arm 2 G-CSF 
strategy b 
Arm 2: N 
analysed 
Arm 2: days 
primary G- 
CSF 
FN 
definition 
Pegfilgrastim vs. no primary G-CSF  
Vogel 
2005[19] 
RCT, 
phase III, 
DB 
Breast 
cancer 
62% stage IV, 
38% other 
stages 
Mean age 
52, range 
21-88 
Docetaxel 
100mg/m2 
4 3 weeks Pegfilgrastim 
primary: 6mg day 2 
463 1 Placebo primary, 
pegfilgrastim 
secondary (following 
FN) 
465 0 Fever + ANC 
<0.5x109/l 
a Romieu 
2007[21] 
RCT, 
phase II, 
OL 
Breast 
cancer 
Stage II-III, 
node-positive 
Age ≥65. 
Median 68, 
range 65-77 
FEC-100 6 (FN 
reported 
cycle 1 only) 
3 weeks Pegfilgrastim 
primary: 6mg day 2 
30 1 No primary G-CSF, 
pegfilgrastim 
secondary (following 
FN or neutropenia) 
29 0 Fever + ANC 
<1x109/l 
a Hecht 
2009[22] 
RCT, 
phase II 
Colorectal 
cancer 
NR NR FOLFOX (49%), 
FOLFIRI (26%) or 
FOIL (25%) 
4 2 weeks Pegfilgrastim 
primary: 6mg day 4 
123 1 Placebo primary 118 0 Grade 3-4 
FN (assumed 
fever + ANC 
<1x109/l) 
a Balducci 
2007: solid 
tumour[20] 
RCT, OL Solid tumour 
(lung, 
ovarian, 
breast) 
31% stage I-II, 
69% stage III- 
IV 
Age ≥65. 
Median 72, 
range 65-88 
One of 15 
regimens with 
mild-to-moderate 
risk of neutropenia 
6 3 weeks Pegfilgrastim 
primary: 6mg day 2 
343 1 No primary G-CSF, 
pegfilgrastim 
secondary (at 
physician’s 
discretion) 
343 0 Fever + ANC 
<1x109/l 
a Balducci 
2007: 
NHL[20] 
RCT, OL NHL 38% stage I-II, 
62% stage III- 
IV 
Age ≥65. 
Median 72, 
range 65-88 
CHOP or R-CHOP 6 3 weeks Pegfilgrastim 
primary: 6mg day 2 
73 1 No primary G-CSF, 
pegfilgrastim 
secondary (at 
physician’s 
discretion) 
73 0 Fever + ANC 
<1x109/l 
Filgrastim vs. no primary G-CSF  
Doorduijn 
2003[23] 
RCT, OL Aggressive 
NHL 
Stage II-IV Age ≥65. 
Median 72, 
range 65-90 
CHOP 6 to 8 3 weeks Filgrastim primary: 
300ug/d from day 2 
for 10d 
197 10 No primary G-CSF 192 0 FN not 
defined in 
terms of ANC 
Osby 2003 
(CHOP)[24] 
RCT, OL Aggressive 
NHL 
Stage II-IV Age ≥60. 
Range 60-86 
CHOP 4 to 8 (most 
8) 
3 weeks Filgrastim primary: 
5ug/kg/d from day 2 
up to 14d or until 
ANC=10x109/l 
101 10 to 14 No primary G-CSF 104 0 Fever + ANC 
<0.5x109/l 
Osby 2003 
(CNOP)[24] 
RCT, OL Aggressive 
NHL 
Stage II-IV Age ≥60. 
Range 60-86 
CNOP 4 to 8 (most 
8) 
3 weeks Filgrastim primary: 
5ug/kg/d from day 2 
up to 14d or until 
ANC=10x109/l 
125 10 to 14 No primary G-CSF 125 0 Fever + ANC 
<0.5x109/l 
Zinzani 
1997[25] 
RCT, OL Aggressive 
NHL 
Stage II-IV Age ≥60. 
Age range 
60-82 
VNCOP-B 8 1 week 
(differs 
alternate 
weeks) 
Filgrastim primary: 
5ug/kg/d from day 3; 
prophylactic 
antibiotics 
77 5 No primary G-CSF; 
prophylactic 
antibiotics 
72 0 FN not 
defined in 
terms of ANC 
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Trial Study 
design 
Cancer type Cancer stage Patient age Chemotherapy 
regimen 
N cycles 
(max) 
Cycle 
length 
Arm 1 G-CSF 
strategy b 
Arm 1: N 
analysed 
Arm 1: days 
primary G- 
CSF 
Arm 2 G-CSF 
strategy b 
Arm 2: N 
analysed 
Arm 2: days 
primary G- 
CSF 
FN 
definition 
Pettengell 
1992[26] 
RCT, OL Aggressive 
NHL 
Any stage Age range 
16-71 
VAPEC-B 11 1 week 
(differs 
alternate 
weeks) 
Filgrastim primary: 
230ug/m2/d from day 
2 up to 14d or until 
ANC=10x109/l; 
prophylactic 
antibiotics 
41 12 No primary G-CSF; 
prophylactic 
antibiotics 
39 0 Fever + ANC 
<1x109/l 
Timmer- 
Bonte 
2005[27] 
RCT, 
phase III, 
OL 
SCLC 69% 
extensive, 
31% limited 
Age range 
36-81 
CDE 5 3 weeks Filgrastim primary: 
300/450ug/d from 
day 4; prophylactic 
antibiotics 
90 10 No primary G-CSF; 
prophylactic 
antibiotics 
85 0 Fever + ANC 
<0.5x109/l 
Trillet-Lenoir 
1993[28] 
RCT, DB SCLC 64% 
extensive, 
36% limited 
Median 59 CDE 6 3 weeks Filgrastim primary: 
230ug/m2/d from day 
4 up to 14d or until 
ANC=10x109/l 
65 9 to 14 Placebo primary 64 0 Fever + ANC 
<1x109/l 
Crawford 
1991[29] 
RCT, DB SCLC 72% 
extensive, 
28% limited 
Age range 
31-80 
CDE 6 3 weeks Filgrastim primary: 
230ug/m2/d from day 
4 up to 14d or until 
ANC=10x109/l 
95 9 to 14 Placebo primary; 
secondary G-CSF 
104 0 Fever + ANC 
<1x109/l 
Fossa 
1998[30] 
RCT, 
phase III, 
OL 
Germ cell 
cancer 
Metastatic, 
poor-prognosis 
Age range 
15-65 
BEP/EP or 
BOP/VIP-B 
6 3 weeks or 
10 d 
Filgrastim primary: 
5ug/kg/d from day 3 
or 6 
129 7 or 14 No primary G-CSF 130 0 FN not 
defined in 
terms of ANC 
a del Giglio 
2008[31] 
RCT, DB Breast 
cancer 
21% high-risk 
stage II, 
53% stage III, 
25% stage IV 
Mean age 
51, range 
25-75 
Doxorubicin 
60mg/m2 
/docetaxel 
75mg/m2 
4 (FN 
reported 
cycle 1 only) 
3 weeks Filgrastim primary 
(Neupogen or 
XM02): 5ug/kg/d 
from day 2 up to 14d 
or to ANC=10x109/l 
276 5 to 14 
(median 9- 
10) 
Placebo in cycle 1; 
filgrastim (XM02) in 
subsequent cycles 
72 0 (cycle 1) Fever + ANC 
<0.5x109/l 
Lenograstim vs. no primary G-CSF  
Chevallier 
1995[9] 
RCT, DB Breast 
cancer, 
inflammatory 
Non-metastatic Age range 
23-65 
FEC-high-dose 4 3 weeks Lenograstim 
primary: 5ug/kg/d 
from day 6 
61 10 Placebo primary 59 0 Fever + ANC 
<1x109/l 
Gisselbrecht 
1997[32] 
RCT, DB Aggressive 
NHL 
Any stage Age range 
15-55 
LNH-87 (LNH-84 + 
randomization to 
anthracyclines) 
4 2 weeks Lenograstim 
primary: 5ug/kg/d 
from day 6 
82 8 Placebo primary 80 0 Fever + ANC 
<1x109/l 
Bui 
1995[10] 
RCT, DB Soft tissue 
sarcoma 
Metastatic or 
locally 
advanced 
Age range 
21-69 
MAID 6 (FN 
reported 
cycle 1 only) 
3 weeks Lenograstim primary: 
5ug/kg/d from day 4 
up to 14d or until 
ANC=30x109/l 
22 10 to 14 Placebo primary; 
secondary G-CSF 
26 0 Fever + ANC 
<1x109/l 
Gebbia 
1994[33] 
RCT, DB Various Advanced Age range 
40-75 
Various Various Various Lenograstim 
primary: 5ug/kg/d 
23 ≥7d Placebo primary 28 0 Fever + ANC 
<1x109/l 
Gebbia 
1993[34] 
RCT, DB Various Advanced Age range 
38-66 
Various Various Various Lenograstim 
primary: 5ug/kg/d 
43 7 to 10 Placebo primary 43 0 Fever + ANC 
<1x109/l 
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Trial Study 
design 
Cancer type Cancer stage Patient age Chemotherapy 
regimen 
N cycles 
(max) 
Cycle 
length 
Arm 1 G-CSF 
strategy b 
Arm 1: N 
analysed 
Arm 1: days 
primary G- 
CSF 
Arm 2 G-CSF 
strategy b 
Arm 2: N 
analysed 
Arm 2: days 
primary G- 
CSF 
FN 
definition 
Pegfilgrastim vs. 10- or 11-day filgrastim  
Green 
2003[7] 
RCT, 
phase III, 
DB 
Breast 
cancer 
28% stage II, 
27% stage III, 
45% stage IV 
Mean age 
52, range 
30-75 
Doxorubicin 
60mg/m2 
/docetaxel 
75mg/m2 
4 3 weeks Pegfilgrastim 
primary: 6mg day 2; 
then placebo up to 
14d 
77 1 Filgrastim primary: 
5ug/kg, from day 2 
up to 14d or until 
ANC=10x109/l 
75 11 (median) Fever + ANC 
<0.5x109/l 
Holmes 
2002: phase 
III[8] 
RCT, 
phase III, 
DB 
Breast 
cancer 
High-risk stage 
II, III or IV. 
37% stage IV 
Mean age 51 Doxorubicin 
60mg/m2 
/docetaxel 
75mg/m2 
4 3 weeks Pegfilgrastim 
primary: 100ug/kg 
day 2; then placebo 
up to 14d 
149 1 Filgrastim primary: 
5ug/kg, from day 2 
up to 14d or until 
ANC=10x109/l 
147 11 (mean) Fever + ANC 
<0.5x109/l 
Holmes 
2002: phase 
II[35] 
RCT, 
phase II, 
DF 
Breast 
cancer 
High-risk stage 
II, III or IV. 
30% stage IV 
Mean age 49 Doxorubicin 
60mg/m2 
/docetaxel 
75mg/m2 
4 3 weeks Pegfilgrastim 
primary: 100ug/kg 
day 2 (other dose 
groups not included 
here) 
46 1 Filgrastim primary: 
5ug/kg, from day 2 
up to 14d or until 
ANC=10x109/l 
25 10.6; 10.2; 
10.4; 11.0 
(mean in 
cycles 1-4) 
Fever + ANC 
<0.5x109/l 
Grigg 
2003[36] 
RCT, 
phase II, 
OL, DF 
NHL Any stage Age ≥60. 
Mean 68, 
range 60-82 
CHOP 6 3 weeks Pegfilgrastim 
primary: 100ug/kg 
day 2 (other dose 
groups not included 
here) 
14 1 Filgrastim primary: 
5ug/kg, from day 2 
up to 14d or until 
ANC=10x109/l 
13 10 (mean) Fever + ANC 
<0.5x109/l 
Vose 
2003[37] 
RCT, 
phase II, 
OL 
NHL (n=56) 
or HL (n=4) 
Relapsed or 
refractory 
Mean age 
49. 85% <65 
ESHAP 4 (FN 
reported 
cycles 1 & 2 
only) 
3 weeks Pegfilgrastim 
primary: 100ug/kg 
day 2 
29 1 Filgrastim primary: 
5ug/kg, from day 2 
up to 12d or until 
ANC=10x109/l 
31 11 (median) Fever + ANC 
<0.5x109/l 
a Studies added as a result of updated search. b  G-CSF strategy: Primary prophylaxis is in all cycles. Secondary prophylaxis is in all cycles following FN, or following FN or neutropenia, or at physician’s 
discretion (as noted for individual studies). ANC=absolute neutrophil count; DB=double-blind; DF=dose-finding; HL= Hodgkin’s lymphoma; NHL=non-Hodgkin’s lymphoma; OL=open-label; SCLC=small-cell 
lung cancer. 
 
Chemotherapy regimens used: FEC-100=5-fluorouracil 500mg/m2, epirubicin 100mg/m2, cyclophosphamide 500mg/m2. FEC-high-dose=5-fluorouracil 750mg/m2, epirubicin 35mg/m2, cyclophosphamide 
400mg/m2. TAC= doxorubicin 50mg/m2, cyclophosphamide 500mg/m2, docetaxel 75mg/m2 CHOP=cyclophosphamide 750mg/m2, doxorubicin 50mg/m2, vincristine 1.4mg/m2, prednisolone 100mg days 1-5. 
R-CHOP=CHOP plus rituximab. ESHAP= etoposide 40mg/m2, methylprednisolone 500mg, cisplatin 25mg/m2/d, cytarabine 2000mg/m2. LNH-87=cyclophosphamide 1200mg/m2  day 1, vindesine 2mg/m2 
days 1 & 5, bleomycin 10mg days 1 & 5, prednisolone 60mg/m2  days 1-5, methotrexate 15mg, with either doxorubicin 75mg/m2  or mitoxantrone 12mg/m2  day 1. MAID=mesna, doxorubicin, ifosfamide, 
dacarbazine. CNOP=cyclophosphamide 750mg/m2, mitoxantrone 10mg/m2, vincristine 1.4mg/m2, prednisolone 50mg/m2  days 1-5. VNCOP-B=vincristine 2mg, mitoxantrone 10mg/m2, cyclophosphamide 
300mg/m2, etoposide 150mg/m2, prednisone 40mg, bleomycin 10mg/m2. VAPEC-B=vincristine 1.4mg/m2, doxorubicin 35mg/m2 prednisolone 50mg/d (then tapered), etoposide 100mg/m2, cyclophosphamide 
350mg/m2, bleomycin 10mg/m2. CDE=cyclophosphamide 1g/m2, doxorubicin 45-50mg/m2, etoposide 100-120mg/m2. BEP/EP=etoposide 100mg/m2, cisplatin 20mg/m2, plus or minus bleomycin 30 U. 
BOP/VIP-B=bleomycin 30 U, vincristine 2mg, cisplatin 20-50mg/m2/etoposide 100mg/m2, ifosfamide 1000mg/m2. FOIL=5-FU, oxaliplatin, irinotecan, leucovorin. FOLFOX=5-FU, oxaliplatin, leucovorin. 
FOLFIRI=5-FU, irinotecan, leucovorin. 
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Table 2: Summary of febrile neutropenia incidence based on meta-analyses of trials of G-CSFs 
 
Treatment 1 Treatment 2 No of 
studies 
No of 
patients 
Relative risk of FN (95% CI), p-value I2 (heterogeneity) 
Pegfilgrastim No primary G-CSF 5 2060 0.30 (0.14 to 0.65), p = 0.002 76% 
Filgrastim No primary G-CSF 10 2183 0.57 (0.48 to 0.69), p < 0.00001 50% 
Lenograstim No primary G-CSF 5 467 0.62 (0.44 to 0.88), p = 0.007 64% 
Any G-CSF No primary G-CSF 20 4710 0.51 (0.41 to 0.62), p < 0.00001 74% 
Pegfilgrastim Filgrastim 5 606 0.66 (0.44 to 0.98), p = 0.04 0% 
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Study or Subgroup Events Total Events Total Weight M-H, Random, 95% CI 
Green 2003 10 77 15 75 30.5% 0.65 [0.31, 1.35] 
Grigg 2003 0 14 1 13 1.7% 0.31 [0.01, 7.02] 
Holmes  2002 (phase  II) 5 46 2 25 6.7% 1.36 [0.28, 6.50] 
Holmes  2002 (phase  III) 14 149 27 147 45.1% 0.51 [0.28, 0.94] 
Vose 2003 6 29 6 31 16.1% 1.07 [0.39, 2.94] 
 
 
Figure 2: Primary G-CSFs versus no primary G-CSF: FN incidence 
 
Primary G-CSF  No primary G-CSF  Risk Ratio  Risk Ratio 
Study or Subgroup 
8.1.1 Pegfilgrastim 
Balducci 2007 (NHL) 
Balducci 2007 (solid) 
Hecht 2009 
Romieu 2007 
Vogel 2005 
Subtotal (95% CI) 
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4.7% 
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2.1% 
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17.1% 
M-H, Random, 95% CI 
 
0.41 [0.22, 0.76] 
0.41 [0.23, 0.75] 
0.29 [0.08, 1.02] 
0.77 [0.23, 2.60] 
0.08 [0.03, 0.18] 
0.30 [0.14, 0.65] 
M-H, Random, 95% CI 
Heterogeneity: Tau² = 0.54; Chi² = 16.49, df = 4 (P = 0.002); I² = 76% 
Test for overall effect: Z = 3.08 (P = 0.002) 
 
8.1.2 Filgrastim 
Crawford 1991 
 
38 
 
95 
 
80 
 
104 
 
7.2% 
 
0.52 [0.40, 0.68] 
del Giglio 2008 34 276 26 72 6.0% 0.34 [0.22, 0.53] 
Doorduijn 2003 72 197 86 192 7.4% 0.82 [0.64, 1.04] 
Fossa 1998 25 129 38 130 5.9% 0.66 [0.43, 1.03] 
Osby 2003 (CHOP) 34 101 52 104 6.8% 0.67 [0.48, 0.94] 
Osby 2003 (CNOP) 40 125 62 125 6.9% 0.65 [0.47, 0.88] 
Pettengell  1992 9 41 17 39 4.3% 0.50 [0.26, 0.99] 
Timmer-Bonte 2005 16 90 27 85 5.2% 0.56 [0.33, 0.96] 
Trillet-Lenoir  1993 17 65 34 64 5.7% 0.49 [0.31, 0.79] 
Zinzani 1997 4 77 15 72 2.6% 0.25 [0.09, 0.72] 
Subtotal (95% CI)  1196  987 58.1% 0.57 [0.48, 0.69] 
Total events 289  437    
Heterogeneity: Tau² = 0.04; Chi² = 18.17, df = 9 (P = 0.03); I² = 50% 
Test for overall effect: Z = 6.03 (P < 0.00001) 
 
8.1.3 Lenograstim 
Bui 1995 
 
5 
 
22 
 
15 
 
26 
 
3.4% 
 
0.39 [0.17, 0.91] 
Chevallier 1995 36 61 42 59 7.3% 0.83 [0.64, 1.08] 
Gebbia 1993 5 43 14 43 3.0% 0.36 [0.14, 0.90] 
Gebbia 1994 5 23 18 28 3.5% 0.34 [0.15, 0.77] 
Gisselbrecht  1997 52 82 62 80 7.6% 0.82 [0.67, 1.00] 
Subtotal (95% CI)  231  236 24.9% 0.62 [0.44, 0.88] 
Total events 103  151    
Heterogeneity: Tau² = 0.08; Chi² = 11.25, df = 4 (P = 0.02); I² = 64% 
Test for overall effect: Z = 2.70 (P = 0.007) 
 
Total (95% CI) 
Total events 
 
430 
2459  
742 
2251 100.0% 0.51 [0.41, 0.62] 
Heterogeneity: Tau² = 0.13; Chi² = 73.83, df = 19 (P < 0.00001); I² = 74% 
Test for overall effect: Z = 6.54 (P < 0.00001) 
Test for subgroup differences:  Not applicable 
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Figure 3: Pegfilgrastim versus filgrastim: FN incidence* 
 
Pegfilgrastim Filgrastim Risk Ratio  Risk Ratio 
M-H, Random, 95% CI 
 
 
 
 
 
 
Total (95% CI) 
Total events 
315 
35 
291 
51 
100.0% 0.66 [0.44, 0.98] 
Heterogeneity: Tau² = 0.00; Chi² = 2.60, df = 4 (P = 0.63); I² = 0% 
Test for overall  effect: Z = 2.04 (P = 0.04) 
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* In the Holmes 2002 (phase II) study,[35] FN incidence in the filgrastim arm was reported as 2/25, which was incorrectly converted to 12%. The 
absolute numbers (2/25) have been used in this analysis. Therefore the resulting relative risk differs slightly from that reported in the previous 
systematic review by Pinto (2007),[17] which used the 12% figure. 
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Appendix 1: Search strategy (Medline) 
 
1 Granulocyte colony-stimulating factor/ 
2 Granulocyte colony-stimulating factor, recombinant/ 
3 Colony-stimulating factors, recombinant/ 
4 Filgrastim/ 
5 G-CSF$ 
6 granulocyte colony-stimulating factor$ 
7 filgrastim 
8 Neupogen 
9 pegfilgrastim 
10 Neulasta 
11 lenograstim 
12 Granocyte 
13 Euprotin 
14 r-metHuG-CSF 
15 SD-01 
16 PEG-rmetHuG-CSF 
17 XM02 
18 Ratiograstim 
19 or/1-18 
20 randomized controlled trial.pt. 
21 controlled clinical trial.pt. 
22 randomized controlled trial/ 
23 random allocation/ 
24 double blind method/ 
25 single blind method/ 
26 clinical trial.pt. 
27 exp clinical trial/ 
28 (clin$ adj25 trial$).ti,ab. 
29 ((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or mask$)).ti,ab. 
30 placebos/ 
31 placebos.ti,ab. 
32 random.ti,ab. 
33 research design/ 
34 randomised.ti,ab 
35 randomized.ti,ab 
36 or/20-35 
37 19 and 36 
(“$” indicates truncations; “/” indicates subject headings) 
